JP2022519274A5 - - Google Patents

Info

Publication number
JP2022519274A5
JP2022519274A5 JP2021545383A JP2021545383A JP2022519274A5 JP 2022519274 A5 JP2022519274 A5 JP 2022519274A5 JP 2021545383 A JP2021545383 A JP 2021545383A JP 2021545383 A JP2021545383 A JP 2021545383A JP 2022519274 A5 JP2022519274 A5 JP 2022519274A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
pain
optionally substituted
treating
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021545383A
Other languages
English (en)
Japanese (ja)
Other versions
JP7511567B2 (ja
JP2022519274A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016440 external-priority patent/WO2020163244A1/en
Publication of JP2022519274A publication Critical patent/JP2022519274A/ja
Publication of JP2022519274A5 publication Critical patent/JP2022519274A5/ja
Application granted granted Critical
Publication of JP7511567B2 publication Critical patent/JP7511567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021545383A 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法 Active JP7511567B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962800996P 2019-02-04 2019-02-04
US62/800,996 2019-02-04
US201962851433P 2019-05-22 2019-05-22
US62/851,433 2019-05-22
US201962894167P 2019-08-30 2019-08-30
US62/894,167 2019-08-30
US201962937618P 2019-11-19 2019-11-19
US62/937,618 2019-11-19
US202062962647P 2020-01-17 2020-01-17
US62/962,647 2020-01-17
PCT/US2020/016440 WO2020163244A1 (en) 2019-02-04 2020-02-03 Methods for treating symptoms and disorders associated with lysosomal storage diseases

Publications (3)

Publication Number Publication Date
JP2022519274A JP2022519274A (ja) 2022-03-22
JP2022519274A5 true JP2022519274A5 (https=) 2023-02-10
JP7511567B2 JP7511567B2 (ja) 2024-07-05

Family

ID=69743942

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021545375A Pending JP2022520747A (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2021545383A Active JP7511567B2 (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP2025018867A Pending JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021545375A Pending JP2022520747A (ja) 2019-02-04 2020-02-03 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025018867A Pending JP2025072556A (ja) 2019-02-04 2025-02-07 リソソーム蓄積性疾患と関連する症状および障害を処置するための方法

Country Status (13)

Country Link
US (2) US20220016092A1 (https=)
EP (2) EP3920913A1 (https=)
JP (3) JP2022520747A (https=)
KR (2) KR20210123353A (https=)
CN (2) CN113645969A (https=)
AU (2) AU2020217659B2 (https=)
BR (2) BR112021015172A2 (https=)
CA (1) CA3128039A1 (https=)
IL (3) IL285304B2 (https=)
MX (2) MX2021009384A (https=)
SG (2) SG11202107842QA (https=)
TW (3) TW202045168A (https=)
WO (2) WO2020163245A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN114040762A (zh) 2019-02-04 2022-02-11 建新公司 使用葡糖神经酰胺合酶(gcs)的抑制剂治疗纤毛疾病
JP2023512366A (ja) 2020-02-03 2023-03-27 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する神経学的症状を処置するための方法
AU2021311131B2 (en) 2020-07-24 2026-02-19 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (https=) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
KR101987736B1 (ko) * 2011-03-18 2019-06-11 젠자임 코포레이션 글루코실세라마이드 합성효소 억제제
CA2840224C (en) * 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
JO3713B1 (ar) * 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
EP3079695B1 (en) 2013-12-11 2021-03-17 Genzyme Corporation Glucosylceramide synthase inhibitors
TW201642855A (zh) * 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法

Similar Documents

Publication Publication Date Title
JP2022519274A5 (https=)
US10195213B2 (en) Chemical entities that kill senescent cells for use in treating age-related disease
ES2952727T3 (es) Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
KR20150041634A (ko) 시스타티오닌-γ-리아제(ＣＳＥ) 억제제
JP2016528276A (ja) プラーク退縮を促進するための組成物及び治療法
JP2012500800A (ja) 神経因性疼痛の治療法
US20220340650A1 (en) Combination therapy with cgrp antagonists
US20150328188A1 (en) Combination Therapies for the Treatment of Proliferative Disorders
WO2019046287A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
JP2022533981A5 (https=)
IL313808A (en) Methods for treating symptoms and disorders associated with lysosomal storage diseases
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
JP2022520747A5 (https=)
US6455567B1 (en) Method of treatment
JP4739760B2 (ja) バルビツール酸誘導体を使用する運動障害の治療方法
JP7369693B2 (ja) てんかん性の疾患、障害、または病態の処置に使用するためのプロベネシド
JP2018522049A5 (https=)
CN110290788A (zh) 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途
US20020147206A1 (en) Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy
JP7337081B2 (ja) レストレスレッグズ症候群を治療するための治療薬
US11723895B2 (en) Sphingosine pathway modulating compounds for the treatment of coronavirus infection
JP7356968B2 (ja) 心血管疾患に有用な医薬
TWI837197B (zh) 胺基甲酸酯化合物於預防、緩解或治療糖尿病周邊神經病變或化療誘發的周邊神經病變的用途